Pyoderma Gangrenosum with an Underlying Leukocyte Adhesion Deficiency Type 1 (LAD-1) and Pregnancy in the Shade of COVID-19 Epidemic: A Patient and Physician Experience

Aleksandra Opalińska; Adrian Burdacki; Konrad Kwaśniak; Katarzyna Pogoda; Jacek Tabarkiewicz; Adam Reich

doi:10.1007/s13555-021-00507-x

Pyoderma Gangrenosum with an Underlying Leukocyte Adhesion Deficiency Type 1 (LAD-1) and Pregnancy in the Shade of COVID-19 Epidemic: A Patient and Physician Experience

Dermatol Ther (Heidelb). 2021 Jun;11(3):643-653. doi: 10.1007/s13555-021-00507-x. Epub 2021 Mar 8.

Authors

Aleksandra Opalińska¹, Adrian Burdacki², Konrad Kwaśniak³, Katarzyna Pogoda³, Jacek Tabarkiewicz³, Adam Reich⁴

Affiliations

¹ Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland.
² Department of Hematology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland.
³ Department of Immunology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland.
⁴ Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland. adi_medicalis@go2.pl.

Abstract

In the first part of this article, the anonymous patient diagnosed with leukocyte adhesion deficiency type 1 (LAD-1) and pyoderma gangrenosum (PG) discusses her experience of her medical history and treatment in a foreign country during her pregnancy and the coronavirus disease-19 (COVID-19) pandemic. The patient's dermatologists, immunologist, and diagnostician refer to the epidemiology, genetics, diagnosis, morphologic manifestations, including skin lesions, treatment, and prognosis in LAD-1. The patient's diagnostic and therapeutic process was discussed in the last part of this paper.

Keywords: COVID-19; Cyclosporine; Leukocyte adhesion deficiency type 1; Prednisolone; Pregnancy; Pyoderma gangrenosum.

Publication types

Letter